Study on the efficacy and safety of Remimazolam in one lung ventilation.
- Conditions
- ung Neoplasms
- Registration Number
- JPRN-UMIN000045849
- Lead Sponsor
- Kitasato University, School of Medicine, Department of Anesthesiology
- Brief Summary
An abstract of this study was presented at Euroanaesthesia 2023 (Glasgow, 2023). It has not yet been published as a paper and details will be published at the time of the paper's publication. There were no significant differences in oxygenation capacity at each time point. However, ephedrine use was significantly lower in the remimazolam group than in the propofol group.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 70
Not provided
If the research subject refuses to cooperate in the research. Contraindications to the use of anesthetics. If the subject has a disease that affects HPV. In the case of a procedure in which one lung ventilation is frequently released intraoperatively, such as surgery for pneumothorax. Patients with longitudinal tumors in the supine position who may require only short periods of one-lung ventilation. If the patient is scheduled to receive intraoperative cardiopulmonary ventilation. Patients with severe chronic lung disease (1 sec rate 50%or less, % lung capacity less than 80%)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To analyze the frequency and severity of hypoxemia in the remimazolam and propofol groups. During anesthesia, arterial partial pressure of oxygen, inhaled oxygen concentration, and P/F ratio (arterial partial pressure of oxygen/Inhaled oxygen concentration) immediately before one-lung ventilation, 30 minutes after the start of one-lung ventilation, and 1 hour after the start of six-lung ventilation.
- Secondary Outcome Measures
Name Time Method